EP
Eversept Partners Portfolio holdings
AUM
$992M
This Quarter Return
+2.43%
1 Year Return
+2.54%
3 Year Return
+103.47%
5 Year Return
+181.01%
10 Year Return
–
AUM
$1.21B
AUM Growth
+$1.21B
(-3.2%)
Cap. Flow
-$36.6M
Cap. Flow
% of AUM
-3.03%
Top 10 Holdings %
Top 10 Hldgs %
49.32%
Holding
122
New
19
Increased
31
Reduced
32
Closed
17
Top Buys
Top Sells
| 1 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$60.1M |
| 2 |
Bristol-Myers Squibb
BMY
|
$27.8M |
| 3 |
Labcorp
LH
|
$26M |
| 4 |
CTLT
CATALENT, INC.
CTLT
|
$24.5M |
| 5 |
Masimo
MASI
|
$18.1M |
Sector Composition
| 1 | Healthcare | 93.47% |
| 2 | Industrials | 1.55% |
| 3 | Technology | 0.08% |
| 4 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $89.8M | 5.74% | 833,750 +199,080 | +31% | +$21.5M |
|
2
Community Health Systems
CYH
$387M
| $85M | 5.43% | 6,389,538 +401,375 | +7% | +$5.34M |
|
3
United Therapeutics
UTHR
$13.8B
| $84.7M | 5.41% | 391,920 -52,551 | -12% | -$11.4M |
|
4
Danaher
DHR
$147B
| $56M | 3.58% | 170,053 +22,115 | +15% | +$7.28M |
|
5
AstraZeneca
AZN
$248B
| $55.3M | 3.53% | 949,224 +58,416 | +7% | +$3.4M |
|
6
Ascendis Pharma
ASND
$11.8B
| $54.3M | 3.47% | 403,678 -41,525 | -9% | -$5.59M |
|
7
Avantor
AVTR
$9.18B
| $47.4M | 3.03% | 1,125,465 -166,549 | -13% | -$7.02M |
|
|
BHVN
8
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $43.4M | 2.77% | +315,129 | New | +$43.4M |
|
9
ARK Genomic Revolution ETF
ARKG
$1.04B
| $40.7M | 2.6% | 664,484 -25,017 | -4% | -$1.53M |
|
10
Envista
NVST
$3.52B
| $38.3M | 2.44% | 849,298 +38,417 | +5% | +$1.73M |
|
|
AMRN
11
Amarin Corp
AMRN
$311M
| $35.6M | 2.28% | 10,573,302 -1,031,688 | -9% | -$3.48M |
|
12
McKesson
MCK
$85.4B
| $33.9M | 2.17% | 136,111 -25,597 | -16% | -$6.37M |
|
13
Amneal Pharmaceuticals
AMRX
$3B
| $30.9M | 1.97% | 6,440,572 -409,262 | -6% | -$1.96M |
|
14
GSK
GSK
$79.9B
| $25M | 1.6% | 567,205 +165,551 | +41% | +$7.31M |
|
15
Celldex Therapeutics
CLDX
$1.47B
| $22.9M | 1.46% | +592,478 | New | +$22.9M |
|
|
OCDX
16
DELISTED
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
| $19M | 1.21% | 886,140 -28,846 | -3% | -$617K |
|
|
RCM
17
DELISTED
R1 RCM Inc. Common Stock
RCM
| $18.7M | 1.19% | 733,132 -31,648 | -4% | -$807K |
|
18
Centene
CNC
$14.3B
| $18.5M | 1.18% | 224,613 +83,506 | +59% | +$6.88M |
|
19
Teva Pharmaceuticals
TEVA
$21.1B
| $18.4M | 1.18% | 2,301,498 -1,253,306 | -35% | -$10M |
|
20
Icon
ICLR
$13.8B
| $16.1M | 1.03% | 51,867 -20,044 | -28% | -$6.21M |
|
21
Elevance Health
ELV
$71.8B
| $15.9M | 1.02% | 34,294 +2,666 | +8% | +$1.24M |
|
22
Fate Therapeutics
FATE
$120M
| $14.9M | 0.95% | 254,790 -6,105 | -2% | -$357K |
|
23
HealthEquity
HQY
$7.72B
| $14.7M | 0.94% | 333,352 +218,974 | +191% | +$9.69M |
|
|
24
Labcorp
LH
$23.1B
| $14.3M | 0.91% | 45,522 -82,789 | -65% | -$26M |
|
25
Humana
HUM
$36.5B
| $12.7M | 0.81% | 27,382 +3,299 | +14% | +$1.53M |
|